Mustang Bio (MBIO) vs Revelation Biosciences (REVB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Mustang Bio is the larger company by market cap ($3.2 million vs $3.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MBIO | REVB |
|---|---|---|
| Share price | $0.4202 | $0.76 |
| Market cap | $3.18M | $3.03M |
| 1-day change | +2.46% | -2.56% |
| P/E ratio (TTM) | — | 0.17 |
| EPS (TTM) | $-0.44 | $4.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.81 | $5.96 |
| 52-week low | $0.3802 | $0.75 |
| Distance from 52-week high | -76.78% | -87.25% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +2235.53% |
| Average volume | 29.38K | 39.50K |
| Shares outstanding | 6.73M | 3.98M |
| Employees | 4 | 8 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Mustang Bio
MBIO stock →Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Revelation Biosciences
REVB stock →Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
MBIO vs REVB FAQ
Which is bigger, Mustang Bio or Revelation Biosciences?
Mustang Bio (MBIO) is larger, with a market capitalization of $3.18M compared with $3.03M for Revelation Biosciences (REVB).
Are Mustang Bio and Revelation Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.